Market Research Reports, Inc. has announced the addition of “EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023” research report to their offering.
Lewes, DE -- (SBWIRE) -- 11/03/2014 -- Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action (Resmini, 2014). CS is associated with increased mortality caused by complications due to excess cortisol (Resmini, 2014). This epidemiological analysis focuses on CS, and four subtypes of CS: Cushing’s disease, ectopic-adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS.
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to ?85 years) and sex in these markets. Additionally, Publisher epidemiologists provide the immediate outcome of transsphenoidal adenomectomy surgery (TSS) in patients with Cushing’s disease.
For this analysis, Publisher epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.
Publisher epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate (AGR) of 0.59%. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases. Additionally, each of the 6MM will see an increase in diagnosed prevalent cases over the 10-year forecast period, except for Germany, which will have a negative AGR of 0.14%. Because Publisher epidemiologists applied a constant diagnosed prevalence in each of the 6MM, the trends in the diagnosed prevalent cases of CS are attributed to changing population demographics in the 6MM.
Spanning over 58 pages, “EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023” report covering the Introduction, Epidemiology, Appendix.
Know more about this report at – http://mrr.cm/ZVY
Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: